A Phase I Study of INCB024360 (Epacadostat) Alone, INCB024360 in Combination With Pembrolizumab (MK-3475), and INCB024360 and Pembrolizumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors (KEYNOTE-434)

Trial Profile

A Phase I Study of INCB024360 (Epacadostat) Alone, INCB024360 in Combination With Pembrolizumab (MK-3475), and INCB024360 and Pembrolizumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors (KEYNOTE-434)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer; Colon cancer; Duodenal cancer; Gastric cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions
  • Acronyms KEYNOTE-434
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 24 Nov 2017 Planned End Date changed from 31 Jan 2020 to 30 Jun 2020.
    • 09 Nov 2017 Planned number of patients changed from 42 to 60.
    • 30 Oct 2017 Primary results (n=15) presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top